Literature DB >> 12930356

Critical roles of CD30/CD30L interactions in murine autoimmune diabetes.

S Chakrabarty1, M Nagata, H Yasuda, L Wen, M Nakayama, S A Chowdhury, K Yamada, Z Jin, R Kotani, H Moriyama, O Shimozato, H Yagita, K Yokono.   

Abstract

CD30/CD30L is a member of tumour necrosis factor (TNF) receptor/TNF superfamily and has been implicated in immune-regulation. A genetic study has also suggested a possible implication of CD30 in spontaneous autoimmune diabetes in NOD mice. In this study, we investigated the involvement of CD30/CD30L in the development of diabetes in NOD mice. Flow cytometric analysis showed that CD30 and CD30L were highly expressed on CD4+ or CD8+ T cells in the spleen and pancreatic lymph node of younger NOD mice. In addition, islet-specific CD4+ or CD8+ T cell lines expressed CD30 and CD30L. Administration of a neutralizing anti-CD30L monoclonal antibody (mAb) from 2 to 10 week of age completely suppressed the development of spontaneous diabetes in NOD mice. In addition, the treatment with anti-CD30L mAb also inhibited the development of diabetes induced by adoptive transfer of spleen cells from diabetic NOD mice or islet-specific CD4+ or CD8+ T cell lines into NOD-SCID mice. Furthermore, anti-CD30L mAb inhibited T cell proliferation in response to islet antigens. These results suggested that CD30/CD30L interaction plays important roles in both induction and effector phases of autoimmune diabetes in NOD mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930356      PMCID: PMC1808783          DOI: 10.1046/j.1365-2249.2003.02223.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  CD134L engagement enhances human B cell Ig production: CD154/CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent B cell responses.

Authors:  S Morimoto; Y Kanno; Y Tanaka; Y Tokano; H Hashimoto; S Jacquot; C Morimoto; S F Schlossman; H Yagita; K Okumura; T Kobata
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

Review 2.  CD30:CD30 ligand interactions in the immune response.

Authors:  S Opat; J S Gaston
Journal:  Autoimmunity       Date:  2000       Impact factor: 2.815

3.  Determination of islet cell antibodies by immunofluorescence.

Authors:  B M Dean; R Pujol-Borrell; G F Botazzo
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

4.  Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion.

Authors:  R Arens; K Tesselaar; P A Baars; G M van Schijndel; J Hendriks; S T Pals; P Krimpenfort; J Borst; M H van Oers; R A van Lier
Journal:  Immunity       Date:  2001-11       Impact factor: 31.745

5.  Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.

Authors:  U Schwab; H Stein; J Gerdes; H Lemke; H Kirchner; M Schaadt; V Diehl
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

6.  Analysis of the mouse CD30 gene: a candidate for the NOD mouse type 1 diabetes locus Idd9.2.

Authors:  T Siegmund; N Armitage; L S Wicker; L B Peterson; J A Todd; P A Lyons
Journal:  Diabetes       Date:  2000-09       Impact factor: 9.461

7.  Fas/Fas ligand interactions play an essential role in the initiation of murine autoimmune diabetes.

Authors:  Maki Nakayama; Masao Nagata; Hisafumi Yasuda; Kenji Arisawa; Reiko Kotani; Katsumi Yamada; Shahead Ali Chowdhury; Sagarika Chakrabarty; Zhen Zi Jin; Hideo Yagita; Koichi Yokono; Masato Kasuga
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

8.  Insulin antibodies in insulin-dependent diabetics before insulin treatment.

Authors:  J P Palmer; C M Asplin; P Clemons; K Lyen; O Tatpati; P K Raghu; T L Paquette
Journal:  Science       Date:  1983-12-23       Impact factor: 47.728

9.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus.

Authors:  Margarida Saraiva; Philip Smith; Padraic G Fallon; Antonio Alcami
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  5 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games.

Authors:  Thomas Hehlgans; Klaus Pfeffer
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

Review 3.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

Authors:  C Baker; L Chang; K A Elsegood; A J Bishop; D H Gannon; P Narendran; N J Leech; C M Dayan
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

5.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.